Latest news
{{'2023-05-26T07:27:17Z' | dateFormatFilter}}
Novo Nordisk A/S: Once-weekly Sogroya® (somapacitan) receives CHMP positive opinion for expanded use in children and adolescents with growth hormone deficiency
Read more
{{'2023-05-24T09:58:45Z' | dateFormatFilter}}
Novo Nordisk and Life Edit Therapeutics establish multi-target collaboration to discover and develop gene editing therapies for rare and cardiometabolic diseases
Read more
{{'2023-05-22T14:01:25Z' | dateFormatFilter}}
Novo Nordisk A/S: Oral semaglutide 50 mg achieved 15.1% weight loss (17.4% if all people adhered to treatment) in adults with obesity or overweight in the OASIS 1 trial
Read more
Progress towards zero environmental impact
Being respected for adding value to society
Ensure distinct core capabilities and evolve culture
Further raise the innovation-bar for diabetes treatment
Develop a leading portfolio of superior treatment solutions for obesity
Strengthen and progress the Rare disease pipeline
Establish presence in Other serious chronic diseases focusing on CVD, NASH and CKD
Strengthen Diabetes leadership - aim at global value market share of more than 1/3
More than 25 billion DKK in Obesity sales by 2025
Secure a sustained growth outlook for Rare disease
Deliver solid sales and operating profit growth:
- Deliver 6-10% sales growth in International Operations
- Transform 70% of sales in the USA1
Drive operational efficiencies across the value chain to enable
investments in future growth assets
Deliver free cash flow to enable attractive capital allocation to shareholders
Investors
Share price
{{priceData.date}} {{priceData.time}}